Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer.

CONCLUSIONS: Everolimus demonstrated predictable toxicity in advanced and heavily pretreated patients with mCRPC. No clinical or clear pathologic effects despite downstream TORC1 target inhibition, suggesting that single agent everolimus has no clinical utility in men with mCRPC. PMID: 31522863 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31522863?dopt=Abstract

Source: Urologic Oncology - September 11, 2019 Category: Urology & Nephrology Authors: George DJ, Halabi S, Healy P, Jonasch D, Anand M, Rasmussen J, Wood SY, Spritzer C, Madden JF, Armstrong AJ Tags: Urol Oncol Source Type: research